Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$31.60
-2.9%
$42.34
$13.57
$53.08
$2.16B1.94722,445 shs636,293 shs
CureVac stock logo
CVAC
CureVac
$2.31
-8.0%
$3.08
$2.21
$12.36
$517.16M2.51816,321 shs1.24 million shs
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
$11.80
-5.6%
$13.25
$6.42
$15.51
$2.63B1.67343,504 shs258,611 shs
MultiPlan Co. stock logo
MPLN
MultiPlan
$0.57
-1.7%
$0.87
$0.54
$2.29
$374.90M0.61.65 million shs1.98 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
-2.89%-7.84%-22.93%-14.20%+16.48%
CureVac stock logo
CVAC
CureVac
-7.97%-5.33%-21.43%-35.29%-68.23%
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
-5.60%-8.67%-16.73%-10.94%+71.26%
MultiPlan Co. stock logo
MPLN
MultiPlan
-1.89%-22.52%-24.41%-45.12%-39.13%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arvinas, Inc. stock logo
ARVN
Arvinas
2.7569 of 5 stars
4.40.00.00.02.72.50.6
CureVac stock logo
CVAC
CureVac
4.0504 of 5 stars
3.04.00.04.92.20.01.3
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
3.6068 of 5 stars
3.53.00.00.02.40.83.1
MultiPlan Co. stock logo
MPLN
MultiPlan
0.5079 of 5 stars
2.01.00.00.01.91.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arvinas, Inc. stock logo
ARVN
Arvinas
2.88
Moderate Buy$59.7389.03% Upside
CureVac stock logo
CVAC
CureVac
2.00
Hold$8.33260.75% Upside
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
3.00
Buy$47.33301.13% Upside
MultiPlan Co. stock logo
MPLN
MultiPlan
N/AN/A$2.00250.39% Upside

Current Analyst Ratings

Latest GTBIF, CVAC, MPLN, and ARVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2024
CureVac stock logo
CVAC
CureVac
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$12.00 ➝ $4.00
4/12/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$90.00 ➝ $87.00
4/5/2024
CureVac stock logo
CVAC
CureVac
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
3/25/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$65.00
2/29/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$26.00 ➝ $60.00
2/29/2024
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$11.00 ➝ $15.50
2/28/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00
2/28/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$89.00 ➝ $90.00
2/28/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$95.00 ➝ $80.00
2/28/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$33.00 ➝ $59.00
2/22/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arvinas, Inc. stock logo
ARVN
Arvinas
$78.50M27.50N/AN/A$11.99 per share2.64
CureVac stock logo
CVAC
CureVac
$72.33M7.15N/AN/A$2.88 per share0.80
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
$1.05B2.35$0.61 per share19.19$8.10 per share1.46
MultiPlan Co. stock logo
MPLN
MultiPlan
$961.52M0.38$0.46 per share1.25$2.64 per share0.22

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arvinas, Inc. stock logo
ARVN
Arvinas
-$367.30M-$6.50N/AN/AN/A-185.09%-70.24%-31.79%5/3/2024 (Estimated)
CureVac stock logo
CVAC
CureVac
-$262.38MN/A0.00N/AN/AN/AN/AN/A6/4/2024 (Estimated)
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
$36.27M$0.1578.6731.05N/A3.44%2.13%1.45%5/1/2024 (Estimated)
MultiPlan Co. stock logo
MPLN
MultiPlan
-$91.70M-$0.15N/AN/A-9.54%-8.31%-2.05%5/8/2024 (Confirmed)

Latest GTBIF, CVAC, MPLN, and ARVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
MultiPlan Co. stock logo
MPLN
MultiPlan
N/AN/AN/AN/AN/AN/A  
2/29/2024Q4 2023
MultiPlan Co. stock logo
MPLN
MultiPlan
N/A-$0.06-$0.06-$0.07N/A$244.14 million    
2/28/2024Q4 2023
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
$0.05$0.01-$0.04$0.01$270.07 million$278.23 million    
2/27/2024Q4 2023
Arvinas, Inc. stock logo
ARVN
Arvinas
-$1.15-$2.53-$1.38-$2.53$38.91 million($43.10) million  

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
CureVac stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
N/AN/AN/AN/AN/A
MultiPlan Co. stock logo
MPLN
MultiPlan
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
4.98
4.98
CureVac stock logo
CVAC
CureVac
0.06
3.56
3.41
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
N/A
2.72
1.82
MultiPlan Co. stock logo
MPLN
MultiPlan
2.65
1.16
1.16

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
CureVac stock logo
CVAC
CureVac
17.26%
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
0.09%
MultiPlan Co. stock logo
MPLN
MultiPlan
87.15%

Insider Ownership

CompanyInsider Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
5.23%
CureVac stock logo
CVAC
CureVac
2.15%
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
11.90%
MultiPlan Co. stock logo
MPLN
MultiPlan
8.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
44568.31 million64.74 millionOptionable
CureVac stock logo
CVAC
CureVac
1,049223.88 million219.07 millionOptionable
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
4,600210.36 million185.33 millionNot Optionable
MultiPlan Co. stock logo
MPLN
MultiPlan
2,800644.37 million591.53 millionOptionable

GTBIF, CVAC, MPLN, and ARVN Headlines

SourceHeadline
Top 2 Health Care Stocks Which Could Rescue Your Portfolio This Month - Agenus (NASDAQ:AGEN), MultiPlan (NYSE:MPLN)Top 2 Health Care Stocks Which Could Rescue Your Portfolio This Month - Agenus (NASDAQ:AGEN), MultiPlan (NYSE:MPLN)
benzinga.com - April 23 at 8:36 AM
MultiPlan CEO talks strategy, recent criticismMultiPlan CEO talks strategy, recent criticism
axios.com - April 18 at 3:23 PM
MultiPlan Corporation Announces First Quarter 2024 Earnings Conference CallMultiPlan Corporation Announces First Quarter 2024 Earnings Conference Call
businesswire.com - April 16 at 8:00 AM
MultiPlan (NYSE:MPLN) Trading Down 4.4%MultiPlan (NYSE:MPLN) Trading Down 4.4%
marketbeat.com - April 9 at 12:12 PM
MultiPlan (NYSE:MPLN) Stock Price Up 6.7%MultiPlan (NYSE:MPLN) Stock Price Up 6.7%
marketbeat.com - April 4 at 3:08 PM
MultiPlan (NYSE:MPLN) Shares Gap Down to $0.81MultiPlan (NYSE:MPLN) Shares Gap Down to $0.81
marketbeat.com - April 1 at 12:44 PM
MultiPlan Corporation Receives Continued Listing Standard Notice from NYSEMultiPlan Corporation Receives Continued Listing Standard Notice from NYSE
businesswire.com - March 29 at 4:30 PM
MultiPlan (NYSE:MPLN) Trading 5.8% Higher MultiPlan (NYSE:MPLN) Trading 5.8% Higher
marketbeat.com - March 27 at 12:44 PM
MPLN Apr 2024 1.000 putMPLN Apr 2024 1.000 put
finance.yahoo.com - March 16 at 2:28 AM
MultiPlan appoints Jerry Hogge as COOMultiPlan appoints Jerry Hogge as COO
msn.com - March 7 at 11:39 AM
MultiPlan Appoints Jerry Hogge as Chief Operating OfficerMultiPlan Appoints Jerry Hogge as Chief Operating Officer
businesswire.com - March 7 at 8:00 AM
MultiPlan Corporation (MPLN) Q4 2023 Earnings Call TranscriptMultiPlan Corporation (MPLN) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 2 at 7:50 AM
Grant of Awards to New MultiPlan CEO, Travis Dalton, under NYSE Listing RulesGrant of Awards to New MultiPlan CEO, Travis Dalton, under NYSE Listing Rules
businesswire.com - March 1 at 6:00 PM
MultiPlan Corporation (NYSE:MPLN) Q4 2023 Earnings Call TranscriptMultiPlan Corporation (NYSE:MPLN) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 1 at 9:34 AM
MultiPlan Reports Fourth Quarter and Full Year 2023 ResultsMultiPlan Reports Fourth Quarter and Full Year 2023 Results
finance.yahoo.com - February 29 at 9:29 AM
MultiPlan Corporation 2023 Q4 - Results - Earnings Call PresentationMultiPlan Corporation 2023 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 29 at 7:50 AM
Multiplan FY 2023 Earnings PreviewMultiplan FY 2023 Earnings Preview
msn.com - February 28 at 2:49 PM
MultiPlan Corporation Announces Fourth Quarter and Full Year 2023 Earnings Conference CallMultiPlan Corporation Announces Fourth Quarter and Full Year 2023 Earnings Conference Call
tmcnet.com - February 1 at 4:20 PM
MultiPlan announces Travis Dalton as new CEOMultiPlan announces Travis Dalton as new CEO
msn.com - January 4 at 8:47 AM
MultiPlan Announces CEO Succession PlanMultiPlan Announces CEO Succession Plan
finance.yahoo.com - January 4 at 8:47 AM
NYSE to Commence Delisting Proceedings with Respect to the Warrants of MultiPlan Corporation (MPLN.WS)NYSE to Commence Delisting Proceedings with Respect to the Warrants of MultiPlan Corporation (MPLN.WS)
tmcnet.com - January 3 at 7:47 PM
MultiPlan Corporation to present at the 42 nd Annual J.P. Morgan Healthcare ConferenceMultiPlan Corporation to present at the 42 nd Annual J.P. Morgan Healthcare Conference
businesswire.com - December 7 at 10:16 AM
MultiPlan Corporation to present at the 42nd Annual J.P. Morgan Healthcare ConferenceMultiPlan Corporation to present at the 42nd Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 6 at 5:49 PM
MultiPlan Corporation (NYSE:MPLN) Q3 2023 Earnings Call TranscriptMultiPlan Corporation (NYSE:MPLN) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 8 at 5:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arvinas logo

Arvinas

NASDAQ:ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
CureVac logo

CureVac

NASDAQ:CVAC
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Green Thumb Industries logo

Green Thumb Industries

OTCMKTS:GTBIF
Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands. It distributes its products primarily to third-party retail customers and sells finished products directly to consumers in its own retail stores, as well as direct-to consumer delivery channel. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.
MultiPlan logo

MultiPlan

NYSE:MPLN
MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.